ID   SK-MEL-204
AC   CVCL_U909
DR   Wikidata; Q54953916
RX   PubMed=1716514;
RX   PubMed=7509835;
RX   PubMed=9598804;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=9598804).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 19-12-24; Version: 8
//
RX   PubMed=1716514;
RA   Albino A.P., Davis B.M., Nanus D.M.;
RT   "Induction of growth factor RNA expression in human malignant
RT   melanoma: markers of transformation.";
RL   Cancer Res. 51:4815-4820(1991).
//
RX   PubMed=7509835; DOI=10.1111/1523-1747.ep12371784;
RA   Bouchard B., Vijayasaradhi S., Houghton A.N.;
RT   "Production and characterization of antibodies against human
RT   tyrosinase.";
RL   J. Invest. Dermatol. 102:291-295(1994).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//